A new study of AxoSim’s Nerve-on-a-Chip technology shows that the platform accurately provides key physiological readouts that could help speed the development of drugs to treat neurological disorders.
The study also shows that Nerve-on-a-Chip technology is the first all-human in vitro model that can measure critical factors that were formerly only available using live animal models. These include robust axonal outgrowth, myelination of human stem cell-derived neurons by primary human Schwann cells, and evaluation of nerve conduction velocity, according to the New Orleans-based company.
Get the full story on our sister site, Drug Delivery Business.